Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of Booster Vaccination With Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell) for the Prevention of SARS-CoV-2 Infection in a Population of 18 Years of Age and Older.
NCT06175494 is registered in ClinicalTrials.gov with WestVac Biopharma Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of Booster Vaccination With Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell) for the Prevention of SARS-CoV-2 Infection in a Population of 18 Years of Age and Older.
- Lead sponsor
- WestVac Biopharma Co., Ltd.
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- December 19, 2023
- Completion date
- January 31, 2025
- Enrollment
- 4,800 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.